Literature DB >> 30863889

Carnosine's inhibitory effect on glioblastoma cell growth is independent of its cleavage.

Henry Oppermann1, Katharina Purcz2, Claudia Birkemeyer3, Rainer Baran-Schmidt2, Jürgen Meixensberger2, Frank Gaunitz2.   

Abstract

The naturally occurring dipeptide carnosine (β-alanyl-L-histidine) inhibits the growth of tumor cells. As its component L-histidine mimics the effect, we investigated whether cleavage of carnosine is required for its antineoplastic effect. Using ten glioblastoma cell lines and cell cultures derived from 21 patients suffering from this malignant brain tumor, we determined cell viability under the influence of carnosine and L-histidine. Moreover, we determined expression of carnosinases, the intracellular release of L-histidine from carnosine, and whether inhibition of carnosine cleavage attenuates carnosine's antineoplastic effect. We observed a significantly higher response of the cells to L-histidine than to carnosine with regard to cell viability in all cultures. In addition, we detected protein and mRNA expression of carnosinases and a low but significant release of L-histidine in cells incubated in the presence of 50 mM carnosine (p < 0.05), which did not correlate with carnosine's effect on viability. Furthermore, the carnosinase 2 inhibitor bestatin did not attenuate carnosine's effect on viability. Interestingly, we measured a ~ 40-fold higher intracellular abundance of L-histidine in the presence of 25 mM extracellular L-histidine compared to the amount of L-histidine in the presence of 50 mM carnosine, both resulting in a comparable decrease in viability. In addition, we also examined the expression of pyruvate dehydrogenase kinase 4 mRNA, which was comparably influenced by L-histidine and carnosine, but did not correlate with effects on viability. In conclusion, we demonstrate that the antineoplastic effect of carnosine is independent of its cleavage.

Entities:  

Keywords:  Carnosinase; Carnosine; Glioblastoma; L-Histidine; Pyruvate dehydrogenase kinase 4

Mesh:

Substances:

Year:  2019        PMID: 30863889     DOI: 10.1007/s00726-019-02713-6

Source DB:  PubMed          Journal:  Amino Acids        ISSN: 0939-4451            Impact factor:   3.520


  7 in total

1.  Carnosine Alleviates Knee Osteoarthritis and Promotes Synoviocyte Protection via Activating the Nrf2/HO-1 Signaling Pathway: An In-Vivo and In-Vitro Study.

Authors:  Prabhakar Busa; Sing-Ong Lee; Niancih Huang; Yaswanth Kuthati; Chih-Shung Wong
Journal:  Antioxidants (Basel)       Date:  2022-06-20

2.  Viability of Glioblastoma Cells and Fibroblasts in the Presence of Imidazole-Containing Compounds.

Authors:  Elisabeth Christiane Seidel; Claudia Birkemeyer; Rainer Baran-Schmidt; Jürgen Meixensberger; Henry Oppermann; Frank Gaunitz
Journal:  Int J Mol Sci       Date:  2022-05-23       Impact factor: 6.208

3.  Carnosine synthase deficiency is compatible with normal skeletal muscle and olfactory function but causes reduced olfactory sensitivity in aging mice.

Authors:  Lihua Wang-Eckhardt; Asisa Bastian; Tobias Bruegmann; Philipp Sasse; Matthias Eckhardt
Journal:  J Biol Chem       Date:  2020-10-09       Impact factor: 5.157

4.  Carnosine inhibits glioblastoma growth independent from PI3K/Akt/mTOR signaling.

Authors:  Henry Oppermann; Helene Faust; Ulrike Yamanishi; Jürgen Meixensberger; Frank Gaunitz
Journal:  PLoS One       Date:  2019-06-27       Impact factor: 3.240

Review 5.  Melatonin's Antineoplastic Potential Against Glioblastoma.

Authors:  Enrico Moretti; Gaia Favero; Luigi Fabrizio Rodella; Rita Rezzani
Journal:  Cells       Date:  2020-03-03       Impact factor: 6.600

6.  The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment.

Authors:  Ina Patties; Sonja Kallendrusch; Lisa Böhme; Eva Kendzia; Henry Oppermann; Frank Gaunitz; Rolf-Dieter Kortmann; Annegret Glasow
Journal:  J Exp Clin Cancer Res       Date:  2019-10-21

7.  Erythrocytes Prevent Degradation of Carnosine by Human Serum Carnosinase.

Authors:  Henry Oppermann; Stefanie Elsel; Claudia Birkemeyer; Jürgen Meixensberger; Frank Gaunitz
Journal:  Int J Mol Sci       Date:  2021-11-26       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.